These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2932981)

  • 1. Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits.
    Shi WZ; Fahey MR; Fisher DM; Miller RD; Canfell C; Eger EI
    Anesthesiology; 1985 Dec; 63(6):584-8. PubMed ID: 2932981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cerebral effects of pancuronium and atracurium in halothane-anesthetized dogs.
    Lanier WL; Milde JH; Michenfelder JD
    Anesthesiology; 1985 Dec; 63(6):589-97. PubMed ID: 2932982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.
    Fahey MR; Rupp SM; Fisher DM; Miller RD; Sharma M; Canfell C; Castagnoli K; Hennis PJ
    Anesthesiology; 1984 Dec; 61(6):699-702. PubMed ID: 6239574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laudanosine, an atracurium and cisatracurium metabolite.
    Fodale V; Santamaria LB
    Eur J Anaesthesiol; 2002 Jul; 19(7):466-73. PubMed ID: 12113608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of laudanosine in dogs.
    Hennis PJ; Fahey MR; Canfell PC; Shi WZ; Miller RD
    Anesthesiology; 1986 Jul; 65(1):56-60. PubMed ID: 3729058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma during intracranial surgery.
    Eddleston JM; Harper NJ; Pollard BJ; Edwards D; Gwinnutt CL
    Br J Anaesth; 1989 Nov; 63(5):525-30. PubMed ID: 2605068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
    Nigrovic V; Banoub M
    Clin Pharmacokinet; 1992 May; 22(5):396-408. PubMed ID: 1505145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU.
    Parker CJ; Jones JE; Hunter JM
    Br J Anaesth; 1988 Nov; 61(5):531-40. PubMed ID: 3207525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atracurium decay and the formation of laudanosine in humans.
    Nigrovic V; Fox JL
    Anesthesiology; 1991 Mar; 74(3):446-54. PubMed ID: 2001023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients.
    Gwinnutt CL; Eddleston JM; Edwards D; Pollard BJ
    Br J Anaesth; 1990 Dec; 65(6):829-32. PubMed ID: 2265055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of central nervous system effects of laudanosine by inhalation anaesthetics.
    Shi WZ; Fahey MR; Fisher DM; Miller RD
    Br J Anaesth; 1989 Nov; 63(5):598-600. PubMed ID: 2605078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage.
    Tassonyi E; Fathi M; Hughes GJ; Chiodini F; Bertrand D; Muller D; Fuchs-Buder T
    Acta Anaesthesiol Scand; 2002 Nov; 46(10):1236-41. PubMed ID: 12421196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular effects of atracurium during halothane-nitrous oxide and enflurane-nitrous oxide anesthesia in humans.
    Rupp SM; McChristian JW; Miller RD
    Anesthesiology; 1985 Jul; 63(1):16-9. PubMed ID: 3160265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome.
    Lefrant JY; Farenc C; De la Coussaye JE; Muller L; Ripart J; Cuvillon P; Saissi G; Eledjam JJ
    Anaesth Intensive Care; 2002 Aug; 30(4):422-7. PubMed ID: 12180578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation.
    Chow B; Bowden MI; Ho E; Weatherley BC; Bion JF
    Br J Anaesth; 2000 Dec; 85(6):850-5. PubMed ID: 11732518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convulsive effects and pharmacokinetics of laudanosine in the rat.
    Scheepstra GL; Vree TB; Crul JF; van de Pol F; Reekers-Ketting J
    Eur J Anaesthesiol; 1986 Sep; 3(5):371-83. PubMed ID: 3780694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion.
    Grigore AM; Brusco L; Kuroda M; Koorn R
    Crit Care Med; 1998 Jan; 26(1):180-3. PubMed ID: 9428564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics.
    Farenc C; Audran M; Lefrant JY; Mazerm I; Bressolle F
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(1):117-26. PubMed ID: 10202964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The possible neuroprotective effect of laudanosine, an atracurium and cisatracurium metabolite.
    Fodale V; Santamaria LB
    Acta Anaesthesiol Scand; 2003 Jul; 47(6):780; 780-1. PubMed ID: 12803601
    [No Abstract]   [Full Text] [Related]  

  • 20. Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration.
    Shearer ES; O'Sullivan EP; Hunter JM
    Br J Anaesth; 1991 Nov; 67(5):569-73. PubMed ID: 1751271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.